medicine

IHH Healthcare to see an exciting 2019 with increasingly palatable valuations: UOB

SINGAPORE (May 31): UOB Kay Hian is maintaining “buy” on IHH Healthcare with a target price of RM6.30 ($2.07), which implies 32.8 times 2020F P/E – well below its historical five-year 12 month forward P/E of 57 times based on the stock’s performance on the KLSE.

This local start-up is using soft robotics to help rehabilitate the hands

SINGAPORE (Mar 22): Roceso Technologies designs and manufactures robotic gloves that are used to help stroke or spinal cord injury patients regain function in their hands through neurological and muscle rehabilitation.

Called EsoGlove, the patent-pending device assists patients in conducting various repetitive tasks. The patient wears the glove, made from fabric and embedded with actuators, and moves as directed by simulations on a screen.

Biolidics partners Japan's Sysmex Corp for cancer-related R&D

SINGAPORE (Feb 20): Biolidics Limited has established a strategic partnership with Sysmex Corporation, a Tokyo Stock Exchange-listed supplier of hematology instruments, to collaborate on the development of laboratory assays in the field of circulating tumour cells.

See: Biolidics selling 27.5 mil new shares at 28 cents each in conjunction with Catalist listing

How immersive technology could drive the future of healthcare

SINGAPORE (Jan 11): Immersive technology is ­increasingly being deployed in various fields other than electronic games and entertainment. 

Take medicine for example, where Singapore start-up BetaSight is using virtual reality (VR) headsets to make the diagnosis of glaucoma easier. 

Glaucoma is an eye condition in which the optic nerve is damaged as a result of ­abnormally high pressure in the eye. If the damage continues, it can cause permanent vision loss. 

Success favours the well-groomed

SINGAPORE (Dec 3): There is a subtle but pervasive trend you might not have noticed: The majority of power players, visionaries and CEOs featured in the media tend to be immaculately groomed. From their full head of hair and glowing skin to their well-pressed suits and leather shoes, these people have mastered the art of making a great first impression.

Categories: 

Tested and proven

SINGAPORE (Nov 5): It is not uncommon to chance upon giant billboards, TV and radio commercials and sponsored events with hair treatment clinics promising a lustrous head of hair, with their “fastest results guaranteed” and “multiple award-winning” treatments.

Cennerv lodges prelim offer documents for Catalist listing, to acquire US subsidiary with proceeds

SINGAPORE (Sept 21): Cennerv Pharmaceuticals on Wednesday lodged its preliminary prospectus ahead of its planned initial public offering (IPO) on the SGX Catalist board.

Cennerv is a Singapore-based pharmaceutical developer specialising in treatments for central nervous system (CNS) disorders with a focus on depression, insomnia, dementia, schizophrenia and autism.

The company intends to use a portion of its proceeds from the exercise to acquire a further 13 million units of Gemeni Therapeutics LLC, a US-based drug development company, for US$200,000 ($272, 700).

Enterprise Singapore and Bpifrance call for proposals on joint France-Singapore innovation projects

SINGAPORE (Sept 18): Enterprise Singapore and Bpifrance are calling for proposals on joint innovation projects in technological and application areas including advanced manufacturing, clean technology and medical technology.

Enterprise Singapore is a statutory board under Singapore’s Ministry of Trade and Industry, while Bpifrance is the agency charged to help French companies develop by providing assistance and financial support.

Clearbridge BioMedics receives $6.6 mil in pre-IPO funding ahead of targeted 4Q launch

SINGAPORE (June 28): Clearbridge BioMedics has announced $6.6 million in pre-initial public offering (IPO) funding from oncology medical professionals, as well as investors focused in healthcare & biotechnology.

The company expects to launch its IPO in 4Q18.

In a Thursday announcement, the clinical stage cancer diagnostics company says it intends to use its latest round of funds for business expansion, technology development, talent recruitment and IPO-related expenses to develop end-to-end cancer diagnostic tests.

Clearbridge partners Australia's Genome.One for personal health genomics programme

SINGAPORE (June 26): Clearbridge Health (CBH) is partnering Australia-based health information company Genome.One, a wholly-owned subsidiary of Garvan Institute of Medical Research, to offer its patients genomic testing and analysis with the latter’s Genome.One GoExplore personal health genomics programme.

The programme sequences and analyses individual DNA samples assess their risk of developing 52 hereditary conditions, including 31 cancers, 13 heart conditions, as well as several other conditions where monitoring or intervention can be of benefit.

Be informed of the stories that matter

Subscribe

Be informed of the stories that matter